0 85

Cited 1 times in

Prognostic factors for resected non-small cell lung cancer in patients with type 2 diabetes mellitus

Authors
 Woo Sik Yu  ;  Chang Young Lee  ;  Seong Yong Park  ;  Jee Won Suh  ;  Kyoung Shik Narm  ;  Dae Joon Kim  ;  Kyung Young Chung  ;  Jin Gu Lee 
Citation
 Journal of Surgical Oncology, Vol.117(5) : 985-993, 2018 
Journal Title
 Journal of Surgical Oncology 
ISSN
 0022-4790 
Issue Date
2018
MeSH
Adenocarcinoma/etiology/*pathology/surgery ; Aged ; Non-Small-Cell Lung/etiology/*pathology/surgery Carcinoma ; Squamous Cell/etiology/*pathology/surgery Carcinoma ; Type 2/*complications Diabetes Mellitus ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/etiology/*pathology/surgery ; Male ; Prognosis ; Retrospective Studies ; Survival Rate
Keywords
carcinoma ; type 2 diabetes mellitus ; hydroxymethylglutaryl-CoA reductase inhibitors ; non-small cell lung ; prognosis
Abstract
BACKGROUND: For diabetic patients with lung cancer, blood glucose levels and medications such as metformin and statins may influence survival. OBJECTIVES: This study aimed to determine prognostic survival factors for diabetic patients with resected non-small cell lung cancer. PATIENTS AND METHODS: Between January 2005 and December 2013, 301 patients with type 2 diabetes mellitus who underwent curative resection for non-small cell lung cancer were identified and reviewed retrospectively. RESULTS: The median follow-up period was 48 months. In multivariate analysis for lung cancer-specific survival, older age, forced expiratory volume in 1 s (FEV1) <80% predicted, and advanced pathologic stage were significant negative prognostic factors; statin use was a positive prognostic factor (hazard ratio (HR), 0.468). In multivariate analysis for overall survival, male sex, older age, comorbidity index, and advanced pathologic stage were significant negative prognostic factors and proper glycemic control (HR, 0.621) and statin use (HR, 0.585) were positive prognostic factors. CONCLUSIONS: Proper glycemic control (glycated hemoglobin A1c <7%) is recommended for diabetic patients undergoing lung cancer operations. Further studies are required to elucidate associations between type 2 diabetes mellitus and antineoplastic effects of statins and to evaluate statins as a novel adjuvant treatment for lung cancer.
Full Text
https://onlinelibrary.wiley.com/doi/abs/10.1002/jso.24989
DOI
10.1002/jso.24989
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Dae Joon(김대준)
Narm, Kyoung Shik(남경식)
Park, Seong Yong(박성용)
Suh, Jee Won(서지원) ORCID logo https://orcid.org/0000-0003-0287-0651
Yu, Woo Sik(유우식)
Lee, Jin Gu(이진구)
Lee, Chang Young(이창영)
Chung, Kyung Young(정경영)
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/162466
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse